S. Kohlfuerst

Posttherapeutic 131I SPECT-CT offers high diagnostic accuracy when the findings on conventional planar imaging are inconclusive and allows a tailored patient treatment regimen

M. Beheshti, P. Mikosch, H. Gallowitsch, 2009, European Journal of Nuclear Medicine and Molecular Imaging.

Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality?

H. Gallowitsch, E. Kresnik, I. Gomez, 2007, European Journal of Nuclear Medicine and Molecular Imaging.

Recombinant human thyrotropin is helpful in the follow-up and 131I therapy of patients with thyroid cancer: a report of the results and benefits using recombinant human thyrotropin in clinical routine.

P. Lind, I. Igerc, S. Kohlfuerst, 2005, Thyroid : official journal of the American Thyroid Association.

Is there a role for sandostatin treatment in patients with progressive thyroid cancer and iodine-negative but somatostatin-receptor-positive metastases?

H. Gallowitsch, E. Kresnik, I. Gomez, 2006, Thyroid : official journal of the American Thyroid Association.

Abstracts of the 33rd International Austrian Winter Symposium

M. Knopp, J. Karp, M. Schwaiger, 2018, EJNMMI Research.

Sentinel node SPECT-CT in breast cancer

P. Mikosch, H. Gallowitsch, E. Kresnik, 2007, Nuklearmedizin.

FDG PET helpful for diagnosing SAPHO syndrome.

P. Lind, I. Igerc, S. Kohlfuerst, 2003, Clinical nuclear medicine.